DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Phase 2

Recruiting

Conditions: TNBC, Triple Negative Breast Cancer

Interventions: Drug: QL1706
Drug: bevacizumab
Drug: Nab paclitaxel

First Posted Date: 2025-01-22

Last Posted Date: 2025-02-06

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT06786026

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Capecitabine in Low Risk Triple Negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Capecitabine

First Posted Date: 2025-01-22

Last Posted Date: 2025-01-22

Lead Sponsor: Fudan University

Target Recruit Count: 198

Registration Number: NCT06787339

Locations: 🇨🇳
breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer

Recruiting

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer

First Posted Date: 2025-01-22

Last Posted Date: 2025-01-22

Lead Sponsor: Fudan University

Target Recruit Count: 600

Registration Number: NCT06786169

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Precision Palliative Care for Patients with Advanced Esophageal Cancer

Conditions: Esophageal Cancer

First Posted Date: 2025-01-22

Last Posted Date: 2025-01-22

Lead Sponsor: Fudan University

Target Recruit Count: 624

Registration Number: NCT06787313

Locations: 🇨🇳
Fudan University, Shanghai, Shanghai, China

ORIENT-31 Regimen in Combination with SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Phase 2

Not yet recruiting

Conditions: NSCLC (advanced Non-small Cell Lung Cancer)
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

Interventions: Drug: ORIENT-31 regimen
Radiation: SBRT

First Posted Date: 2025-01-15

Last Posted Date: 2025-01-21

Lead Sponsor: Fudan University

Target Recruit Count: 53

Registration Number: NCT06775743

Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Irinotecan liposomes combined with cetuximab + vermofenib

First Posted Date: 2025-01-08

Last Posted Date: 2025-02-27

Lead Sponsor: Fudan University

Target Recruit Count: 36

Registration Number: NCT06763029

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors: a Pilot Study Protocol

Not Applicable

Active, not recruiting

Conditions: Musculoskeletal Symptoms
Breast Cancer
Endocrine Therapy
Aromatase Inhibitors

First Posted Date: 2024-12-31

Last Posted Date: 2024-12-31

Lead Sponsor: Fudan University

Target Recruit Count: 24

Registration Number: NCT06754293

Locations: 🇨🇳
Shanghai Cancer Center, ShangHai, XuHui, China

Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric (Stomach) Cancer

Interventions: Drug: Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib

First Posted Date: 2024-12-27

Last Posted Date: 2024-12-27

Lead Sponsor: Fudan University

Target Recruit Count: 141

Registration Number: NCT06748508

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)

Recruiting

Conditions: Metastatic Colorectal Cancer
BRAF V600 Mutation

First Posted Date: 2024-12-27

Last Posted Date: 2024-12-27

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT06749015

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Lymph Node Pathologic Grading Strategy

Recruiting

Conditions: Lung Adenocarcinoma

First Posted Date: 2024-12-20

Last Posted Date: 2024-12-20

Lead Sponsor: Fudan University

Target Recruit Count: 2998

Registration Number: NCT06745830

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy